FDA Adverse Event Injury Summary report: N

XIENCE PROA EVEROLIMUS ELUTING CORONARY STENT SYSTEM

MDR report key: 10165400 · Received June 17, 2020

Report

Report Number
2024168-2020-05121
Event Type
Injury
Date Received
June 17, 2020
Date of Event
May 20, 2020
Report Date
June 17, 2020
Manufacturer
ABBOTT VASCULAR
Product Code
NIQ
PMA / PMN Number
P110019
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
GM
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

THE DEVICE WAS NOT RETURNED FOR EVALUATION. A REVIEW OF THE LOT HISTORY RECORD IDENTIFIED NO MANUFACTURING NONCONFORMITIES ISSUED TO THE REPORTED LOT THAT WOULD HAVE CONTRIBUTED TO THIS EVENT. IT SHOULD BE NOTED THAT THE REPORTED PATIENT EFFECT OF PERFORATION IS LISTED IN THE XIENCE ALPINE (PRO-A) EVEROLIMUS ELUTING CORONARY STENT SYSTEMS INSTRUCTIONS FOR USE AS A KNOWN PATIENT EFFECT OF CORONARY STENTING PROCEDURES. A CONCLUSIVE CAUSE FOR THE REPORTED PATIENT EFFECT, AND THE RELATIONSHIP TO THE PRODUCT, IF ANY, CANNOT BE DETERMINED. THERE IS NO INDICATION OF A PRODUCT QUALITY ISSUE WITH RESPECT TO MANUFACTURE, DESIGN OR LABELING.

Description of Event or Problem · 1

PATIENT ID: (B)(6). IT WAS REPORTED THAT ON (B)(6) 2020, THE PATIENT PRESENTED WITH UNSTABLE ANGINA. A 4.0X28MM XIENCE PROA STENT (1128400-28 8022341) WAS IMPLANTED IN THE PROXIMAL LEFT ANTERIOR DESCENDING (LAD) CORONARY ARTERY LESION WITHOUT A DEVICE ISSUE. FOLLOWING, A PERFORATION OCCURRED. DILATATION WAS PERFORMED AND A 4.0X33MM XIENCE PRO STENT (1128400-33 8011941) WAS IMPLANTED. TWO COVERED, NON-ABBOTT STENTS (PAPYRUS, BIOTRONIK) WERE IMPLANTED, SEALING THE PERFORATION. THE EVENT RESOLVED WITHOUT SEQUELA. POST-PROCEDURE, TIMI FLOW 3 WITH 0% RESIDUAL STENOSIS WAS OBSERVED. NO ADDITIONAL INFORMATION WAS PROVIDED REGARDING THIS ISSUE.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
629091 XIENCE PROA EVEROLIMUS ELUTING CORONARY STENT SYSTEM DRUG ELUTING CORONARY STENT DELIVERY SYSTEM NIQ ABBOTT VASCULAR 8022341

Patients

Seq Age Sex Outcome Treatment
1 63 YR Required Intervention